An overview of the pattern of first- and second-line anti-tuberculosis drug resistance gene mutations

Abstract

Tuberculosis is still the most prevalent infectious cause of mortality, and it has a significant medical, societal, and economic impact MDR-TB is a type of tuberculosis (TB) infection produced by bacteria resistant to at least two of the most important first-line anti-TB treatments, isoniazid, and rifampin. Extensively drug-resistant tuberculosis (XDR-TB) is a type of tuberculosis that is resistant to second-line treatments. MDR-TB is a type of tuberculosis (TB) infection produced by bacteria resistant to at least two of the most important first-line anti-TB treatments, isoniazid, and rifampin. Extensively drug-resistant tuberculosis (XDR-TB) is a type of tuberculosis that is resistant to second-line treatments. Because resistant cases have significant morbidity and mortality, multidrug-resistant tuberculosis poses a significant threat to treatment. The most effective anti-tuberculosis drugs are first-line essential anti-tuberculosis drugs, which must be included in any short-term treatment plan. Rifampicin, ethambutol, Isoniazid, streptomycin, and pyrazinamide are among the medications in this group. Ethionamide, amikacin, capreomycin, and para-aminosalicylic acid are Second-line anti-tuberculosis that are clinically ineffective and cause severe responses far more commonly than first-line drugs. Resistance to first-line drugs was connected to mutations in the pncA, emb­­­­, rpsL, and rrs genes, while rrs, gyrA, eis, tlyA and gryB are associated with second-line drugs.